Neurotech International AI Stock Analysis
Want to see AU:NTI full AI Analyst Report?
Neurotech International (NTI) AI Stock Analysis
Neurotech International
(ASX:NTI)
The overall score is heavily pressured by the company's dire financial state, characterized by zero revenue, deep losses, and a near-complete erosion of equity, which presents a critical going-concern risk. While the stock shows positive short-term price momentum, this technical strength is fragile given the overbought RSI and is fundamentally unsupported by the company's financials or valuation. The debt-free structure is the sole financial bright spot but is insufficient to offset the severe operational and balance sheet weaknesses.
Neurotech International (NTI) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 30.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 4.57M
- Price to Earnings (P/E)
- -4.1
- Beta (1Y)
- 1.00
- Revenue Growth
- -100.00%
- EPS Growth
- 50.49%
- Country
- Australia
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Neurotech International Business Overview & Revenue Model
Company Description
Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and commer...
Neurotech International Financial Statement Overview
Summary
Pre-revenue biotech with zero TTM sales and persistent, deep operating losses exceeding $8M annually. Equity has nearly evaporated to $0.6M, raising going-concern risk. The only mitigant is a debt-free balance sheet and a narrowing cash burn, but the financial foundation is critically weak.
Income Statement
8Very NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 2.44M | 1,963 | 5,959 | 38.26K |
| Gross Profit | 0 | 0 | 2.44M | -5,867 | 4,215 | -535.21K |
| EBITDA | -11.33M | -11.33M | -10.74M | -8.24M | -8.98M | -3.36M |
| Net Income | -6.54M | -6.54M | -10.60M | -5.07M | -7.79M | -3.36M |
Balance Sheet | ||||||
| Total Assets | 2.75M | 2.75M | 3.24M | 12.21M | 5.31M | 2.02M |
| Cash, Cash Equivalents and Short-Term Investments | 2.39M | 2.39M | 3.03M | 11.63M | 5.03M | 1.90M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.14M | 2.14M | 285.74K | 314.70K | 1.35M | 592.98K |
| Stockholders Equity | 611.14K | 611.14K | 2.95M | 11.90M | 3.96M | 1.43M |
Cash Flow | ||||||
| Free Cash Flow | -4.22M | -4.22M | -9.02M | -4.60M | -6.32M | -2.96M |
| Operating Cash Flow | -4.22M | -4.22M | -9.02M | -4.60M | -6.32M | -2.96M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | -3,205 |
| Financing Cash Flow | 3.58M | 3.58M | 429.53K | 11.19M | 9.45M | 26.40K |
Neurotech International Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NTI, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.01, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 71.10 is Negative, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NTI.
Neurotech International Peers Comparison
Overall Rating
AU:COH57Neutral
AU:SOM55Neutral
AU:CMP54Neutral
AU:NTI48Neutral
AU:EMV45.75Neutral
AU:CBL38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 57Neutral | AUD 10.06B | 66.78 | 8.01% | 2.24% | -0.90% | -62.14% | |
| 55Neutral | AUD 68.13M | -25.62 | -5.44% | ― | 2.73% | 25.00% | |
| 54Neutral | AUD 46.94M | 209.09 | 0.93% | ― | 18.54% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | AUD 29.60M | -4.09 | -201.54% | ― | -100.00% | 50.49% | |
| 46Neutral | AUD 132.00M | -15.12 | -46.84% | ― | ― | 20.40% | |
| 38Underperform | AUD 24.49M | -2.12 | -103.48% | ― | -22.43% | 15.02% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:NTI | Neurotech International Ltd. | 0.02 | -0.00 | -5.26% | |
| AU:COH | Cochlear Limited | 153.87 | -107.29 | -41.08% | |
| AU:CMP | Compumedics Limited | 0.23 | -0.09 | -27.69% | |
| AU:SOM | Somnomed Limited | 0.31 | -0.48 | -60.76% | |
| AU:EMV | EMvision Medical Devices Ltd. | 1.42 | -0.34 | -19.32% | |
| AU:CBL | Control Bionics Ltd. | 0.04 | -0.02 | -27.42% |
Neurotech International Corporate Events
Neurotech Issues Shares and Provides Secondary Trading Notice
Neurotech International is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders. Its development program includes NTI164, a broad-spectrum oral cannabinoid drug therapy.Neurotech said it ha...
Neurotech Notifies Issue of Unquoted Options
Neurotech International Limited notified the issue of two classes of unquoted options on November 17, 2026. The notification covers 6,500,000 options at $0.03 dated November 17, 2029, and 13,000,000 options at $0.045 dated November 17, 2030; the rele...
Neurotech Notifies ASX of Two Unlisted Option Classes
Neurotech International Limited notified the ASX of two new classes of unlisted options. The notification covers 11,250,000 options described at $0.02 with a 17 November 2028 date, and 11,250,000 options described at $0.035 with a 17 November 2029 da...
Neurotech International Reports Change in Director’s Share Interests
Neurotech International Limited disclosed a change in director Andrew Chapman’s direct and indirect interests in the company’s fully paid ordinary shares. The notice records the acquisition of 1,000,000 shares for $16,000 on 10 November 2026 and list...
Neurotech International Reports Director Departure and Shareholding
Neurotech International disclosed that Robert Maxwell Johnston ceased serving as a director on 5 November 2026. His final interest notice reported 4,604,761 fully paid ordinary shares held through a related entity, with no directly registered securit...
Neurotech Shareholders Back AGM Resolutions
Neurotech International said all resolutions at its 5 November annual meeting were decided by poll, with shareholders giving strong support to the remuneration report, board elections, capital-raising mandates and ratifications of prior share and opt...
Neurotech advances autism drug NTI164 with Phase 3 trial, FDA IND and new funding
Neurotech International has advanced its autism drug candidate NTI164 into pivotal Phase 3 development, dosing the first patient in its national Beyond Harmony trial in Australia and initiating six hospital sites to enrol up to 200 paediatric ASD pat...
Neurotech Flags High Risks as It Pursues Neurodevelopmental Disorder Therapies
Neurotech International has outlined its strategic focus on developing treatments for neurodevelopmental disorders, emphasizing the inherent risks and uncertainties in drug research and commercialisation. The company highlights that only a small frac...
Neurotech Director Andrew Chapman Boosts Equity Stake
Neurotech International has disclosed a change in director Andrew Chapman’s relevant interests, detailing adjustments in both direct and indirect holdings of fully paid ordinary shares. The notice shows Chapman and related entities acquired 7,900,000...
Neurotech International Releases 2026 Annual Report
Neurotech International has released its 2026 Annual Report, detailing the company’s governance, financial performance, and audited statements for the year. The report outlines board composition, confirms independent auditing and share registry arran...
Neurotech International Sets November AGM, Moves to Digital Meeting Materials
Neurotech International has called its Annual General Meeting for 5 November 2026 at BDO Australia’s Melbourne offices, with shareholder voting eligibility set for those on the register at 4:00 p.m. AEDT on 3 November 2026. The company is shifting to...
Neurotech Starts Pivotal Phase 3 Trial of NTI164 for Autism
Neurotech International has begun dosing the first patient in its pivotal Phase 3 Beyond Harmony trial of NTI164 for children with Autism Spectrum Disorder, moving the cannabinoid-based therapy into late-stage development. The national, multicentre,...
Neurotech International Adds Major Shareholder Andrew Chapman to Board
Neurotech International has appointed Andrew Chapman as a director effective 8 September 2026, signalling a strengthening of its board with an individual closely linked to multiple investment entities. The appointment is accompanied by an update on h...
Neurotech International Options Lapse Simplifies Capital Structure
Neurotech International Limited has confirmed the lapse of 5,000,000 options exercisable at $0.16 and 10,000,000 options exercisable at $0.18, both expiring in February 2030. These options have ceased because the conditions attached to the rights wer...
Neurotech reshapes board as it advances paediatric cannabinoid trials
Neurotech International has announced several board and management changes, appointing Merchant Funds Management founder Andrew Chapman as a non-executive director, bringing more than 25 years of capital markets and biotechnology financing experience...
Neurotech Discloses Final Director Interest as Anthony Filippis Steps Down
Neurotech International Limited has announced that director Anthony Filippis ceased to be a director on 7 September 2026, triggering a final disclosure of his relevant interests in the company’s securities. While he holds no shares directly, his inte...
Neurotech Narrows Loss as R&D Grants Drive Revenue Surge
Neurotech International reported an 86% rise in revenues to $4.8 million for the year ended 30 June 2026, driven almost entirely by a substantial increase in R&D grant income. Despite this uplift, the company remains loss-making, but narrowed its los...
Neurotech Elevates Mark Davies to Executive Chairman as Phase III Cannabinoid Program Advances
Neurotech International, a clinical-stage biopharmaceutical developer of cannabinoid-based therapies for paediatric neurological disorders, is advancing its lead oral drug candidate NTI164 through late-stage clinical development. The company’s progra...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026
